Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

September 11, 2020

Study Completion Date

November 16, 2020

Conditions

Endometriosis

Interventions

DRUG

BAY2328065 LSF

20 mg/mL LSF (liquid service formulation), orally

DRUG

BAY2328065 tablet

50 mg tablet, orally

DRUG

Placebo LSF

Matching Placebo LSF, orally

DRUG

Placebo tablet

Matching Placebo tablet, orally

DRUG

Midazolam

1 mg per day, orally

Trial Locations (1)

CRS Clinical Research Services Berlin GmbH, Berlin